nach oben

Die Diabetologie

Erschienen in:

04.04.2022 | Typ-1-Diabetes | CME

Molekulargenetische Diagnostik des Diabetes mellitus

verfasst von: Dr. Harald Grallert, PD Dr. med. Katharina Warncke

Erschienen in: Die Diabetologie | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Diabetes mellitus ist eine durch chronische Hyperglykämie charakterisierte Gruppe von Krankheitsbildern. Während molekulargenetische Analysen zur genauen Diagnose monogener Subtypen bereits weitestgehend Standard sind, ist dieser Ansatz bei polygenen Erkrankungstypen bisher nicht klinisch etabliert. Polygene Risikoscores können aber dazu beitragen, das Risiko einer Entwicklung bestimmter Subtypen und deren Folgeerkrankungen frühzeitig einzuschätzen und potenziell Präventionsmaßnahmen einzuleiten. Vermutlich können sie zudem klassische Risikofaktoren ergänzen und dadurch eine Spezifizierung der Behandlung ermöglichen. Eine tiefgreifende humangenetische Beratung ist in den meisten Fällen essenziell, um den Patienten über Behandlungsmöglichkeiten und Risikoeinschätzungen aufzuklären.

Ahlqvist E et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6:361–369PubMedCrossRef

Wagner R et al (2021) Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med 27:49–57PubMedCrossRef

Ziegler AG, Nepom GT (2010) Prediction and pathogenesis in type 1 diabetes. Immunity 32:468–478PubMedCrossRefPubMedCentral

Patel KA et al (2016) Type 1 diabetes genetic risk score: a novel tool to discriminate monogenic and type 1 diabetes. Diabetes 65:2094–2099PubMedCrossRef

Cooper JD et al (2008) Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet 40:1399–1401PubMedCrossRefPubMedCentral

Lambert AP et al (2004) Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 89:4037–4043PubMedCrossRef

Valdes AM et al (2012) Use of class I and class II HLA loci for predicting age at onset of type 1 diabetes in multiple populations. Diabetologia 55:2394–2401PubMedCrossRefPubMedCentral

Sepe V, Loviselli A, Bottazzo GF (2009) Genetics of type 1A diabetes. N Engl J Med 361:211PubMedCrossRef

Winkler C et al (2019) Identification of infants with increased type 1 diabetes genetic risk for enrollment into primary prevention trials-GPPAD-02 study design and first results. Pediatr Diabetes 20:720–727PubMedCrossRefPubMedCentral

10.

Broome DT, Pantalone KM, Kashyap SR, Philipson LH (2021) Approach to the patient with MODY-monogenic diabetes. J Clin Endocrinol Metab 106:237–250PubMedCrossRef

11.

Pihoker C et al (2013) Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for diabetes in youth. J Clin Endocrinol Metab 98:4055–4062PubMedCrossRefPubMedCentral

12.

Shepherd M et al (2016) Systematic population screening, using biomarkers and genetic testing, identifies 2.5 % of the U.K. pediatric diabetes population with monogenic diabetes. Diabetes Care 39:1879–1888PubMedCrossRef

13.

Shields BM et al (2010) Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53:2504–2508PubMedCrossRef

14.

Chakera AJ et al (2015) Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care 38:1383–1392PubMedCrossRef

15.

American Diabetes Association (2020) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 43:S14–S31CrossRef

16.

Awa WL et al (2011) Reclassification of diabetes type in pediatric patients initially classified as type 2 diabetes mellitus: 15 years follow-up using routine data from the German/Austrian DPV database. Diabetes Res Clin Pract 94:463–467PubMedCrossRef

17.

Khan MAB et al (2020) Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. J Epidemiol Glob Health 10:107–111PubMedCrossRefPubMedCentral

18.

Zaharia OP et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7:684–694PubMedCrossRef

19.

Mahajan A et al (2018) Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 50:1505–1513PubMedCrossRefPubMedCentral

20.

McCarthy MI et al (2008) Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 9:356–369PubMedCrossRef

21.

Gaulton KJ et al (2015) Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet 47:1415–1425PubMedCrossRefPubMedCentral

22.

Dimas AS et al (2014) Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 63:2158–2171PubMedCrossRefPubMedCentral

23.

Mulder H (2017) Melatonin signalling and type 2 diabetes risk: too little, too much or just right? Diabetologia 60:826–829PubMedCrossRef

24.

Tuomi T et al (2016) Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab 23:1067–1077PubMedCrossRef

25.

Zaharia OP et al (2020) Role of patatin-like phospholipase domain-containing 3 gene for hepatic lipid content and insulin resistance in diabetes. Diabetes Care 43:2161–2168PubMedCrossRef

26.

Ingelsson E, McCarthy MI (2018) Human genetics of obesity and type 2 diabetes mellitus: past, present, and future. Circ Genom Precis Med 11:e2090PubMedCrossRefPubMedCentral

27.

Florez JC, Hirschhorn J, Altshuler D (2003) The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 4:257–291PubMedCrossRef

28.

Udler MS, McCarthy MI, Florez JC, Mahajan A (2019) Genetic risk scores for diabetes diagnosis and precision medicine. Endocr Rev 40:1500–1520PubMedCrossRefPubMedCentral

29.

Knowler WC et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef

30.

Lindstrom J et al (2003) The Finnish diabetes prevention study (DPS): lifestyle intervention and 3‑year results on diet and physical activity. Diabetes Care 26:3230–3236PubMedCrossRef

31.

Maassen JA et al (2004) Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes 53(1):S103–109PubMedCrossRef

32.

Norose T, Ito Y, Ohike N (2020) Two autopsy cases of mitochondrial disease (MELAS and MERRF) with special reference to the histological and immunohistochemical findings of the pancreatic islets. Pathol Int 70:915–917PubMedCrossRef

33.

Broedl UC, Goke B (2006) Molecular diagnosis of diabetes mellitus. Internist (Berl) 47:47–54CrossRef

34.

Kirkwood A, Stuart G, Harding L (2018) Donohue syndrome: a review of literature, case series, and anesthetic considerations. Paediatr Anaesth 28:23–27PubMedCrossRef

35.

Krook A, Brueton L, O’Rahilly S (1993) Homozygous nonsense mutation in the insulin receptor gene in infant with leprechaunism. Lancet 342:277–278PubMedCrossRef

36.

Moller DE, Flier JS (1988) Detection of an alteration in the insulin-receptor gene in a patient with insulin resistance, acanthosis nigricans, and the polycystic ovary syndrome (type A insulin resistance). N Engl J Med 319:1526–1529PubMedCrossRef

37.

Foss-Freitas MC, Akinci B, Luo Y, Stratton A, Oral EA (2020) Diagnostic strategies and clinical management of lipodystrophy. Expert Rev Endocrinol Metab 15:95–114PubMedCrossRef

38.

Garg A et al (1999) A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab 84:3390–3394PubMedCrossRef

39.

Magre J et al (2001) Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 28:365–370PubMedCrossRef

40.

Garg A, Fleckenstein JL, Peshock RM, Grundy SM (1992) Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J Clin Endocrinol Metab 75:358–361PubMed

41.

Brown RJ et al (2016) The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab 101:4500–4511PubMedCrossRefPubMedCentral

42.

Garg A, Peshock RM, Fleckenstein JL (1999) Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 84:170–174PubMed

43.

Lotta LA et al (2017) Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet 49:17–26PubMedCrossRef

44.

Cao H, Hegele RA (2000) Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet 9:109–112PubMedCrossRef

45.

Agarwal AK, Garg A (2002) A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87:408–411PubMed

46.

Gandotra S et al (2011) Perilipin deficiency and autosomal dominant partial lipodystrophy. N Engl J Med 364:740–748PubMedCrossRefPubMedCentral

47.

Nolis T (2014) Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet 59:16–23PubMedCrossRef

48.

Bingham A et al (2008) Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine 87:70–86PubMedCrossRef

Titel: Molekulargenetische Diagnostik des Diabetes mellitus
verfasst von: Dr. Harald Grallert
PD Dr. med. Katharina Warncke
Publikationsdatum: 04.04.2022
Verlag: Springer Medizin
Schlagwörter: Typ-1-Diabetes
Typ-2-Diabetes
MODY-Formen
Insuline
Insuline
Sulfonylharnstoffe
Diabetes mellitus
Erschienen in: Die Diabetologie / Ausgabe 6/2022
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI: https://doi.org/10.1007/s11428-022-00876-7

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft.

Zu den Praxisempfehlungen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Akutes diabetisches Fußsyndrom

Schilddrüsenhormone und nichtalkoholische Fettleber bei Diabetes

Effekt des Mikrobioms auf Statinwirkung und -nebenwirkung

Erratum zu: Diabetes im Alter – Unterstützung Pflegebedürftiger und ihres Umfeldes

Hyperglykämische Notfälle in der ambulanten Versorgung

Mitteilungen des BDE

Praxisempfehlungen der Deutschen Diabetes Gesellschaft